| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Wushanicaritin targets multiple pathways. It exhibits significant antioxidant activity. It has antitumor effects and anti-inflammatory properties. As a prenylated flavonol, it may interact with various signaling pathways involved in oxidative stress, inflammation, and cell proliferation. Its mechanism involves scavenging free radicals and modulating inflammatory and proliferative pathways.
|
|---|---|
| ln Vitro |
Wushan icariin is a naturally occurring polyphenol compound that exhibits a range of biological functions. Icaridin (IC50=35.3 μM) exhibits strong antioxidant activity similar to vitamin C (IC50=32.0 μM) according to the diphenylpicrylhydrazyl free radical (DPPH) free radical scavenging activity test [1].
In vitro, wushanicaritin exhibits significant antioxidant activity with an IC50 of 35.3 μM in DPPH radical scavenging activity tests, comparable to Vitamin C (IC50 = 32.0 μM). It has antitumor effects and anti-inflammatory properties. Its activity is typically evaluated using DPPH radical scavenging assays, cell viability assays in cancer cell lines, and assays measuring inflammatory cytokine production. However, specific IC50 values for antitumor and anti-inflammatory activities are not extensively reported. |
| ln Vivo |
In vivo activity of wushanicaritin has not been extensively characterized in published literature. As a natural flavonoid from Epimedium, it has potential therapeutic applications in oxidative stress-related diseases, cancer, and inflammation. However, specific in vivo efficacy data, including dosing regimens and animal models, are not detailed in the available literature. Further studies are needed to fully characterize its in vivo pharmacological profile.
|
| Enzyme Assay |
Cell-free assays for wushanicaritin involve evaluating its antioxidant activity. DPPH radical scavenging assays are performed by incubating the compound with DPPH radicals and measuring the decrease in absorbance. IC50 values (35.3 μM) are determined from dose-response curves. The compound's chemical purity and identity are confirmed by HPLC, NMR, and mass spectrometry. It is typically dissolved in DMSO or ethanol for assay preparation.
|
| Cell Assay |
In vitro cellular assays for wushanicaritin typically involve treating cancer cells or immune cells with various concentrations of the compound. Cell viability is assessed using MTT or similar assays. Anti-inflammatory activity is assessed by measuring cytokine production in activated immune cells. Antioxidant activity is assessed by measuring ROS levels using fluorescent probes. The compound is typically dissolved in DMSO and diluted in cell culture medium.
|
| Animal Protocol |
In vivo animal studies for wushanicaritin are conducted in models of cancer, inflammation, and oxidative stress. The compound is administered via various routes including oral gavage or intraperitoneal injection. Tumor growth is monitored in cancer models. Inflammatory markers and oxidative stress markers are measured in serum and tissues. However, specific dosing regimens and experimental protocols are not extensively documented in the available literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of wushanicaritin include a molecular weight of 386.40 g/mol and molecular formula C21H22O7. As a flavonoid, it is expected to have moderate oral bioavailability. The compound is typically stored at appropriate conditions as a research reagent. Detailed ADME parameters such as half-life, Cmax, and AUC are not extensively reported in the available literature.
|
| Toxicity/Toxicokinetics |
The toxicity profile of wushanicaritin has not been extensively characterized in published literature. As a natural flavonoid from Epimedium, it is generally considered to have a favorable safety profile at research doses. Standard preclinical safety studies would include acute and sub-chronic toxicity assessments in rodent models. The compound is intended for research use only and not for therapeutic applications in humans.
|
| References | |
| Additional Infomation |
Wushanicaritin is a flavonoid from Epimedium with significant antioxidant activity (DPPH IC50 = 35.3 μM) comparable to Vitamin C. It also has antitumor and anti-inflammatory properties. Its molecular formula is C21H22O7 with a molecular weight of 386.40 g/mol. Wushanicaritin is a research tool for studying oxidative stress, cancer, and inflammation. It is not for therapeutic use.
|
| Molecular Formula |
C21H22O7
|
|---|---|
| Molecular Weight |
386.40
|
| Exact Mass |
386.136
|
| CAS # |
521-45-9
|
| PubChem CID |
12310757
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.405±0.06 g/cm3
|
| Boiling Point |
624.3±55.0 °C at 760 mmHg
|
| LogP |
3.4
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
28
|
| Complexity |
606
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)(CCC1=C2C(=C(C=C1O)O)C(=O)C(=C(O2)C3=CC=C(C=C3)OC)O)O
|
| InChi Key |
VAYWXTLNNGACLF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H22O7/c1-21(2,26)9-8-13-14(22)10-15(23)16-17(24)18(25)19(28-20(13)16)11-4-6-12(27-3)7-5-11/h4-7,10,22-23,25-26H,8-9H2,1-3H3
|
| Chemical Name |
3,5,7-trihydroxy-8-(3-hydroxy-3-methylbutyl)-2-(4-methoxyphenyl)chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~9.62 mg/mL (~24.90 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5880 mL | 12.9400 mL | 25.8799 mL | |
| 5 mM | 0.5176 mL | 2.5880 mL | 5.1760 mL | |
| 10 mM | 0.2588 mL | 1.2940 mL | 2.5880 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
